Stocks Health care ESLA
NASDAQ · Health careEstrella Immunopharma, Inc. (ESLA)
It posted a net loss of $10M. At June 30, 2026 it held $100K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Estrella Immunopharma, Inc. does
Estrella Immunopharma, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ESLA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$13.1M | -$0.35 | n/a |
| 2024 | n/a | -$7.3M | -$0.27 | n/a |
| 2024 | n/a | -$11.1M | -$36.35 | n/a |
| 2022 | n/a | -$996.1K | n/a | n/a |
| 2021 | n/a | -$247.7K | n/a | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Estrella Immunopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- August 21, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- June 30, 2026
- May 27, 2026Proxy statement DEF 14A
- May 18, 2026
- May 18, 2026Late quarterly report notice NT 10-Q
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- April 30, 2026
Insider trades
What the people running Estrella Immunopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 25, 2026 | Liu ChengCEO, Director | Exercised options | 100,000 | $81.5K |
| August 18, 2026 | Xu JiandongChief Financial Officer | Exercised options | 100,000 | $81.5K |
| October 7, 2025 | Xu JiandongChief Financial Officer | Bought | 1,000 | $1.3K |
Who owns ESLA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
2 insiders reported holding 779,625 shares in total, about $375K at the last price.
| Holder | Shares |
|---|---|
| Liu ChengCEO, Director | 397,437 |
| Xu JiandongChief Financial Officer | 382,18816,700 held indirectly |
Questions about ESLA
What does Estrella Immunopharma, Inc. do?
Estrella Immunopharma, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ESLA.
Is Estrella Immunopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $10M.
When did Estrella Immunopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from September 8, 2026.
Similar companies
Compare ESLA with
Follow ESLA
Get an email when Estrella Immunopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ESLA: get an email when it filesWhere the numbers come from
Financial figures are the values Estrella Immunopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.